Hot Products

BR-Xanthone A
Catalog No: CFN99224

Reference standards.

Bryonolic acid
Catalog No: CFN98260

Bryonolic acid has cytotoxic, anti-allergic, anti-inflammatory and antioxidant activities, it can reduce the inflammatory mediator NO by suppressing the expression of the inflammatory enzyme inducible nitric oxide synthase (iNOS) in LPS-activated RAW 264.7 macrophage cells. Bryonolic acid may be a promising neuroprotective agent for the treatment of cerebral ischemia disease, it can protect PC12 cells against NMDA-induced apoptosis by inhibiting Ca2+ influx and regulating gene expression in the Ca2+-CaMKII-CREB signal pathway.

Bryonolol
Catalog No: CFN90562

Reference standards.

Buddlejasaponin IV
Catalog No: CFN98519

Buddlejasaponin IV has analgesic and anti-inflammatory effects, the inhibitions of the expressions of iNOS, COX-2, TNF-alpha, IL-1beta and IL-6 by blocking NF-kappaB activation. Buddlejasaponin IV exerts cytotoxic effects against cancer cells,it can induce cell cycle arrest at G2/M phase and apoptosis in immortalized human oral keratinocytes, it may possess antimetastatic potential by inducing anoikis and upregulating NAG-1 expression. Buddlejasaponin IV can inhibit intrinsic and extrinsic hyperlipidemia and hypercholesterolemia in the rat.

Buddlejasaponin IVb
Catalog No: CFN90709

Buddlejasaponin IVb(200 uM) can shorten thrombin time (TT) by 20.6 %, suggests that it has hemostasis efficacy.

Buddlenoid A
Catalog No: CFN95025

Buddlenoid A shows high inhibition of mushroom tyrosinase.

Bufalin
Catalog No: CFN99947

Bufalin a major digoxin-like immunoreactive component of the Chinese medicine Chan Su; has been shown to exert a potential for anticancer activity against various human cancer cell lines in vitro. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators steroid receptor coactivator (SRC)-3 and SRC-1, it also as a potentially broad-spectrum small-molecule inhibitor for cancer. Bufalin can partly reverse the MDR of K562/VCR cells, with a possible mechanism of down-regulating MRP1 expression and activating apoptosis pathway by altering Bcl-xL/Bax ratio.

Bufarenogin
Catalog No: CFN90151

ψ-Bufarenogin has inhibitory activity on human kidney Na(+)/K(+)-ATPase, it has cytotoxicity against HepG2 and MCF-7 human cancer cells.ψ-Bufarenogin exhibits potent therapeutic effect in xenografted human hepatoma without notable side effects,at least partially,via inhibiting receptor tyrosine kinases-regulated signaling.

Bufotaline
Catalog No: CFN98545

Bufotalin is a cardiotoxic bufanolide steroid, cardiac glycoside analogue. Bufotalin has anti-cancer activity, it can induce apoptosis in Hep 3B cells, and caspase-8 inhibitor (Z-IETD) or wide-ranging caspase inhibitor (Z-VAD) significantly suppresses the bufotalin-induced apoptosis. Bufotalin is a powerful sensitizer of death receptor-induced apoptosis in cancer cells, it promotes death receptor-mediated cell death, especially TRAIL-induced apoptosis, through activation of caspase-3 and PARP-1.

Bufotenine
Catalog No: CFN91165

Bufotenine may have hallucinogenic potential, the presence and levels of bufotenine might be useful and important markers of some psychiatric disorders. Bufotenine is able to block rabies virus infection in BHK-21 cells.